samedan logo
 
 
 
spacer
home > ebr > summer 2018 > calibrating expectations
PUBLICATIONS
European Biopharmaceutical Review

Calibrating Expectations

In Europe and the US, biosimilar drugs are gaining acceptance among physicians, payers, and patients in areas such as kidney disease, growth disorders, cancer, and auto-immune conditions. Progress has been slower in diabetes, but the pandemic nature and heavy cost burdens of the illness may fuel demand for biosimilars in the future. Examining the track record of follow-on biologics in other therapeutic areas can suggest constructive ways to envision the future for diabetes.

By many measures, the global epidemic in diabetes dwarfs other public health challenges. An estimated 60 million Europeans and 30 million Americans have diabetes today. In the US, about 1.5 million people are diagnosed with the disease each year. Many of them patients have transitioned from prediabetes, which affects 84 million Americans. The economic toll is also difficult to ignore.

Direct medical costs linked to diabetes come to about $237 billion a year in the US – more than for any other illness. Insulin and other anti-diabetic drugs, along with treatments for complications, make up 45% of total direct costs.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Rafal Kokolus brings to Syneos Health more than 10 years of combined pharma consulting and drug development/commercialisation experience. He has supported several major pharma and biotech companies in maximising the commercial value of pipeline and in-line assets and optimising marketing and brand strategy. Rafal earned an MBA from University of Western Ontario’s Richard Ivey School of Business, Canada, and a BSc in cell biology and genetics from the University of British Columbia, Canada, and a Graduate Diploma in business administration from Simon Fraser University, Canada.

Dr Doug Niven specialises in pricing and market access at Syneos Health where he has been for the last six years. Prior to this, Doug worked within PwC’s Healthcare Strategy practice. Doug holds a PhD in physics from the University of Birmingham, UK, and a BSc in economics and finance from the University of London, UK.

Rohit Sood leads the global commercial strategy and planning practice at Syneos Health Consulting. During his 12 years at Syneos, he has advised clients in the areas of portfolio planning, commercialisation and launch excellence, and corporate strategy. Rohit has worked with several clients helping them think through their biosimilar go-to-market strategy.
spacer
Rafal Kokolus
spacer
spacer
spacer
Dr Doug Niven
spacer
spacer
spacer
Rohit Sood
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Shionogi Announces Publication of Two Studies in The Lancet Infectious Diseases Highlighting The Efficacy And Safety of Cefiderocol For The Treatment of Infections Due to Aerobic Gram-Negative Bacteria in Adults With Limited Treatment Options

Shionogi announces publication of data from two of its clinical trials; APEKS-NP and CREDIBLE-CR in the journal The Lancet Infectious Diseases.
More info >>

White Papers

Crossing the Blood Brain Barrier (BBB): Which Route to Take?

Aptar Pharma

Aptar Pharma recently hosted an expert panel/roundtable on the various approaches to treating central nervous system (CNS) diseases. This international scientific forum was held in Paris, France on December 5th, 2014. The roundtable was organized to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood brain barrier (BBB) and successfully treating a host of CNS diseases.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement